Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 3 jahren - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010), haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010) 15 µg, haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

nycomed deutschland gmbh (8051959) - basisches bismutgallat; titandioxid; lidocainhydrochlorid 1 h<2>o; bufexamac - zäpfchen und salbe - teil 1 - zäpfchen; basisches bismutgallat (00350) 100 milligramm; titandioxid (00785) 100 milligramm; lidocainhydrochlorid 1 h<2>o (01693) 10 milligramm; bufexamac (11559) 250 milligramm; teil 2 - salbe; basisches bismutgallat (00350) 50 milligramm; titandioxid (00785) 50 milligramm; lidocainhydrochlorid 1 h<2>o (01693) 5 milligramm; bufexamac (11559) 50 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

c.brady gmbh & co. kg - hamamelidis folium (auszug); ichthammolum; titandioxid; zinkoxid - zink-haltige mittel

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zentiva pharma gmbh (8075753) - basisches bismutgallat; titandioxid; lidocainhydrochlorid 1 h<2>o; bufexamac - creme - teil 1 - creme; basisches bismutgallat (00350) 50 milligramm; titandioxid (00785) 50 milligramm; lidocainhydrochlorid 1 h<2>o (01693) 5 milligramm; bufexamac (11559) 50 milligramm

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

urgo - ichthammol; titandioxid; zinkoxid - salbe - ichthammol 15 mg/g; titandioxid 50 mg/g; zinkoxid 150 mg/g - zinc products